Bristol-Myers Squibb Company (NYSE:BMY) is included among the Best Low Risk Stocks for a Retirement Stock Portfolio.
Janux Therapeutics said on January 22 that it has partnered with Bristol-Myers Squibb Company to develop a new cancer treatment, according to Reuters. The announcement was well received by the market, with Janux shares jumping more than 12% in premarket trading. The therapy is aimed at solid tumors, cancers that grow as masses in organs like the lung, breast, colon, or pancreas. Janux said the drug is designed to target a tumor marker that shows up across several cancer types, which could give it wider use if development is successful.
Chief executive David Campbell described the agreement as a major step forward for the company. He said the collaboration combines Janux’s proprietary technology with Bristol Myers’ experience in advancing drugs through clinical development and bringing them to market.
Janux will be responsible for completing preclinical testing before handing off the program to Bristol Myers for clinical trials. Bristol will then lead later-stage development and global commercialization. Janux will remain involved during the early clinical phase.
Bristol-Myers Squibb Company is a global biopharmaceutical company focused on discovering, developing, and delivering medicines for patients facing serious diseases.
READ NEXT: 15 Best S&P 500 Dividend Stocks to Buy in 2026 and 12 Most Profitable Dividend Stocks to Buy in 2026
